Navigation Links
Silence Therapeutics' Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
Date:11/10/2010

tatic processes that involve blood flow to the lung," stated Klaus Giese, Ph.D., chief scientific officer at Silence Therapeutics.  "Importantly, these data provide us with evidence that Atu027, which targets vascular endothelial cells, may be modulating not only the tumor vasculature itself, but the pulmonary vasculature as well."

"We are very pleased to be able to continue to identify the mechanisms that drive Atu027's therapeutic activity while concurrently advancing the product through its ongoing Phase 1 study.  Building this collection of novel data on Atu027 will only serve to inform our ongoing development efforts and allow us to maximize the opportunity for success with this program," said Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.

Atu027, a liposomal AtuRNAi™ formulation in clinical development for systemic cancer indications, is one of the most clinically advanced RNAi therapeutics in the area of oncology.  In June 2009, Silence initiated an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid (malignant) tumors involving single, as well as, repeated intravenous administration.  The study is expected to be completed early in the second half of 2011.

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular upta
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... 6 Omeros Corporation today announced that The Michael ... against milestones to support the Company,s collaboration with The ... new target for the treatment of Parkinson,s disease. Located ... Omeros is the first to link its novel target ...
... N.Y., Jan. 6 Dedicated to the memory ... fields of angiogenesis and vasculogenesis and shed light on the ... special double issue (Volume 6, Number 3-4) of ... papers that reflect the research impact of one of the ...
... Jan. 6 AutoGenomics, a leader in providing automated, ... been invited and has accepted to present at the ... 2009 at the Westin St. Francis Hotel in San ... CEO will provide an overview of the Company at ...
Cached Biology Technology:Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 2Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 3Festschrift Issue Honoring Judah Folkman, M.D. in Lymphatic Research and Biology 2Festschrift Issue Honoring Judah Folkman, M.D. in Lymphatic Research and Biology 3
(Date:7/9/2014)... how a complex protein pivotal in the development of ... discovery answers a key question about one of the ... the subject of tens of thousands of research papers ... Zhang, a research student in Professor Sir Philip Cohen,s ... protein complex, called NF-κB, is activated. The results ...
(Date:7/9/2014)... associate professor of plant pathology and microbiology ... the 2014 Alexopoulos Prize by the Mycological ... the science of mycology the study of fungi ... plant pathogens, and medically important fungi. , The award ... mycologist. Stajich received the award last month in East ...
(Date:7/9/2014)... selection refers to species, selection for traits that are ... natural selection enhances opportunities to mate, the tail of ... the University of California, Riverside have now found that ... placenta are linked. Describing the life histories of ... Poeciliidae, the researchers found that species with placentas tend ...
Breaking Biology News(10 mins):Research reveals how key controller protein is switched on 2UC Riverside plant pathologist receives national recognition 2Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4
... Ph.D., assistant professor of chemistry in Arts & ... the National Institute of Mental Health for research ... Wiring." Maurer,s long term objective is ... a variety of neuronal wiring processes. He is ...
... KSContact with nature has long been suspected to ... from the pain associated with recovery from surgery. ... plants and flowers for patients recovering from abdominal ... and Richard H. Mattson, researchers from the Department ...
... New research in an animal model suggests that a ... a variety of processed foods including meats, cheeses, beverages, ... tumors and may even contribute to the development of ... The study also suggests that dietary regulation of inorganic ...
Cached Biology News:Chemist receives NIH funding to unravel tricks of neuronal wiring 2Flowering plants speed post-surgery recovery 2Common food additive found to increase risk and speed spread of lung cancer 2Common food additive found to increase risk and speed spread of lung cancer 3
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
... Post-Labeling Reactive Dye Pack, 12 x ... specifically optimized for microarray labeling.Higher reactivity ... reactive dye per vial, at > ... individually dispensed, and packed in foil ...
... CyScribe GFX Purification Kit, 24 reactions. ... Cy3- and Cy5-labeled cDNA.Optimized reagents are ... and purification.Flexible and optimized protocols can ... with either Cy3- or Cy5-labeled nucleotides.Reliable ...
Biology Products: